Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Clearside Biomedical Inc

Healthcare US CLSD

NoneUSD
0.00(0%)

Last update at 2026-01-01T20:00:39.380726Z

Day Range

--
LowHigh

52 Week Range

0.922.12
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap77.36M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-25.66000M
  • Revenue TTM7.52M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 1.12M
  • Diluted EPS TTM-0.45

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -32.94700M 0.38M -18.21000M -30.77000M -82.81800M
Minority interest - - - - -
Net income -34.07134M 0.38M -18.03000M -30.55900M -82.81800M
Selling general administrative 11.77M 11.66M 10.76M 16.82M 14.68M
Selling and marketing expenses - - - - -
Gross profit 1.12M 29.57M 7.89M 2.17M 0.03M
Reconciled depreciation 0.14M 0.18M 0.18M 0.21M 0.19M
Ebit -30.27700M -0.62700M -18.11500M -30.51500M -83.13400M
Ebitda -29.60800M -0.44900M -17.93500M -30.30400M -82.94500M
Depreciation and amortization 0.67M 0.18M 0.18M 0.21M 0.19M
Non operating income net other 0.67M 1.00M -0.27500M -0.46600M 0.13M
Operating income -30.27700M -0.62700M -17.93500M -30.30400M -82.94500M
Other operating expenses 31.60M 30.20M 25.83M 32.48M 82.97M
Interest expense 3.34M 1.00M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income -3.33900M - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.12M -1.00300M -0.18000M -0.21100M 0.13M
Total revenue 1.33M 29.57M 7.89M 2.17M 0.03M
Total operating expenses 31.40M 30.20M 25.83M 32.48M 82.97M
Cost of revenue 0.20M - - - 0.00000M
Total other income expense net -2.67000M 1.00M -0.27500M -0.46600M 0.13M
Discontinued operations - - - - -
Net income from continuing ops -29.60800M 0.38M -18.21000M -30.77000M -82.81800M
Net income applicable to common shares -32.94700M 0.38M -18.21000M -30.77000M -82.81800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 34.02M 51.30M 42.90M 19.32M 26.78M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.03M 0.44M 0.78M 0.11M 1.49M
Total liab 49.93M 40.70M 4.93M 10.56M 15.62M
Total stockholder equity -15.91200M 10.61M 37.98M 8.76M 11.16M
Deferred long term liab - - - - -
Other current liab 4.17M 4.18M 3.31M 1.58M 2.93M
Common stock 0.06M 0.06M 0.06M 0.05M 0.04M
Capital stock 0.06M 0.06M 0.06M 0.05M 0.04M
Retained earnings -320.92300M -288.43800M -255.49100M -255.86700M -237.65700M
Other liab - 33.98M - 4.57M 10.47M
Good will - - - - -
Other assets 0.00000M 0.03M 0.16M 0.26M 0.36M
Cash 28.92M 48.26M 30.44M 17.29M 22.59M
Cash and equivalents - - - - -
Total current liabilities 6.81M 5.78M 4.64M 9.94M 10.90M
Current deferred revenue 0.07M 0.20M - 5.00M 5.00M
Net debt 14.08M -46.97300M -29.76100M -15.30700M -16.18600M
Short term debt 0.36M 0.35M 0.39M 1.36M 1.69M
Short long term debt - - - 0.99M 1.33M
Short long term debt total 43.00M 1.28M 0.68M 1.98M 6.41M
Other stockholder equity 304.95M 298.98M 293.41M 264.58M 248.77M
Property plant equipment - 0.76M 0.24M 0.94M 1.20M
Total current assets 30.12M 48.26M 42.14M 18.12M 25.22M
Long term investments - - - - -
Net tangible assets - 10.61M 37.98M 8.76M 11.16M
Short term investments - - - - 0.00000M
Net receivables 0.17M 0.00000M 10.00M - -
Long term debt - - - - 3.82M
Inventory 0.00000M - 0.92M - -
Accounts payable 2.21M 1.05M 0.94M 2.00M 1.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.59700M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.06M 0.05M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - -288.43800M -255.49100M -255.86700M -237.65700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 1.17M 0.16M 0.26M 0.36M
Deferred long term asset charges - - - - -
Non current assets total 3.89M 3.04M 0.77M 1.20M 1.56M
Capital lease obligations 1.01M 1.28M 0.68M 0.99M 1.26M
Long term debt total - - - - 3.82M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.24600M 0.00000M -0.05500M 32.95M -3.67200M
Change to liabilities 0.69M 0.68M -0.63100M -5.58200M -0.31400M
Total cashflows from investing activities -0.24600M -0.24600M -0.05500M 32.92M -3.76000M
Net borrowings - - -4.34900M -5.00000M 1.70M
Total cash from financing activities 31.33M 23.78M 7.87M 8.70M 81.78M
Change to operating activities 10.34M -11.02400M 1.75M -0.71700M -0.56000M
Net income -32.94700M 0.38M -18.21000M -30.77000M -82.81800M
Change in cash 17.72M 13.05M -5.30800M 14.55M -1.18100M
Begin period cash flow 30.70M 17.65M 22.95M 8.40M 9.58M
End period cash flow 48.42M 30.70M 17.65M 22.95M 8.40M
Total cash from operating activities -13.36500M -10.73300M -13.12000M -27.06800M -79.20000M
Issuance of capital stock 0.57M 23.28M 11.96M 13.64M 79.56M
Depreciation 0.14M 0.18M 0.18M 0.21M 0.19M
Other cashflows from investing activities - - - 32.95M -3.67200M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 10.42M -10.86900M - - -
Sale purchase of stock 0.13M 0.50M 0.26M 3.38M 0.52M
Other cashflows from financing activities 30.77M 0.50M 1.25M 0.05M 10.52M
Change to netincome 4.92M 4.06M 3.66M 4.84M 4.94M
Capital expenditures 0.25M 0.25M 0.06M 0.03M 0.09M
Change receivables - - - - -
Cash flows other operating 13.83M -16.02400M 1.88M 4.35M -0.44800M
Exchange rate changes - - - - -
Cash and cash equivalents changes 17.72M 13.05M -5.30800M 14.55M -1.18100M
Change in working capital 11.24M -15.34300M 1.12M -1.29900M -0.87400M
Stock based compensation 4.88M 5.05M 3.60M 4.61M 4.79M
Other non cash items 3.32M -0.99800M 0.19M 0.23M 0.27M
Free cash flow -13.61100M -10.73300M -13.17500M -27.09300M -79.28800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLSD
Clearside Biomedical Inc		 - -% - - - 10.28 3.93 7.18 -2.8404
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical Inc

900 North Point Parkway, Alpharetta, GA, United States, 30005

Key Executives

Name Title Year Born
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. Pres, CEO & Director 1952
Mr. Charles A. Deignan Chief Financial Officer 1964
Dr. Thomas A. Ciulla M.B.A., M.D. Chief Medical Officer & Chief Devel. Officer 1964
Ms. Jenny R. Kobin Head of Investor Relations 1967
Mr. Rick McElheny VP of Corp. Devel. NA
Ms. Susan L. Coultas Ph.D. Chief Clinical Officer NA
Mr. Leslie B. Zacks Sec. 1969
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. President, CEO & Director 1952
Dr. Thomas A. Ciulla M.B.A., M.D. Chairman of Scientific Advisory Board 1965
Mr. Rick McElheny Vice President of Corporate Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.